Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022)

Amylyx Pharmaceuticals (AMLX) has 2 years of Other Accumulated Expenses data on record, last reported at $1.0 million in Q4 2022.

  • For Q4 2022, Other Accumulated Expenses rose 289.53% year-over-year to $1.0 million; the TTM value through Dec 2022 reached $1.0 million, up 289.53%, while the annual FY2022 figure was $1.0 million, 289.53% up from the prior year.
  • Other Accumulated Expenses reached $1.0 million in Q4 2022 per AMLX's latest filing, up from $356000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.0 million in Q4 2022 and bottomed at $258000.0 in Q4 2021.